摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-溴己烷酰胺 | 57817-55-7

中文名称
6-溴己烷酰胺
中文别名
4-(甲磺酰基)苄溴
英文名称
6-bromohexanamide
英文别名
6-bromo-1-hexanamide;6-Bromhexanamid;6-bromohexamide;6-bromo-hexanoic acid amide;6-Brom-hexansaeure-amid;6-Brom-caproamid
6-溴己烷酰胺化学式
CAS
57817-55-7
化学式
C6H12BrNO
mdl
——
分子量
194.071
InChiKey
LGCGXHIRLZORQA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    104-106°C
  • 沸点:
    325.8±25.0 °C(Predicted)
  • 密度:
    1.370±0.06 g/cm3(Predicted)
  • 稳定性/保质期:

    在常温常压下保持稳定。

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    9
  • 可旋转键数:
    5
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    43.1
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi,C
  • 海关编码:
    2924199090
  • WGK Germany:
    3
  • 危险性防范说明:
    P261,P264,P270,P271,P280,P301+P312+P330,P302+P352,P304+P340+P312,P305+P351+P338,P332+P313,P337+P313,P362,P403+P233,P405,P501
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    请将物品存放在密闭、通风干燥的地方。

SDS

SDS:7b6f5cc29f08b15043dc2a525dc893ed
查看

反应信息

点击查看最新优质反应信息

文献信息

  • Hydrosilanes Are Not Always Reducing Agents for Carbonyl Compounds but Can Also Induce Dehydration: A Ruthenium-Catalyzed Conversion of Primary Amides to Nitriles
    作者:Shiori Hanada、Yukihiro Motoyama、Hideo Nagashima
    DOI:10.1002/ejoc.200800523
    日期:2008.8
    A practical procedure for production of nitriles is offered by the triruthenium carbonyl cluster catalyzed dehydration of primary carboxamides with hydrosilanes under neutral conditions. This is the first example that a transition-metal-catalyzed activation of Si–H bonds does not lead to the reduction of carbonyl compounds but to dehydration. Possible mechanisms for the dehydration is discussed on
    在中性条件下,羰基三簇催化伯酰胺与氢硅烷的脱提供了生产腈的实用程序。这是第一个例子,过渡属催化的 Si-H 键活化不会导致羰基化合物的还原,而是导致脱。在中间物种的核磁共振光谱检测的基础上讨论了脱的可能机制。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2008)
  • A catalytic version of hypervalent aryl-λ<sup>3</sup>-iodane-induced Hofmann rearrangement of primary carboxamides: iodobenzene as an organocatalyst and m-chloroperbenzoic acid as a terminal oxidant
    作者:Kazunori Miyamoto、Yuuta Sakai、Shunsuke Goda、Masahito Ochiai
    DOI:10.1039/c2cc16360h
    日期:——
    The first catalytic version of hypervalent aryl-λ3-iodane-induced Hofmann rearrangement of primary carboxamides, which probably involves in situ generation of a tetracoordinated bis(aqua)(hydroxy)phenyl-λ3-iodane complex as an active oxidant from a catalytic amount of iodobenzene by the reaction with m-chloroperbenzoic acid in the presence of HBF4 in dichloromethane–water under mild conditions, was developed.
    首次开发出了基于超价芳基-λ³-烷引发的一级羧酰胺霍夫曼重排反应的催化版本,该方法可能涉及在温和条件下,在二氯甲烷-体系中,通过催化量的碘苯间氯过氧苯甲酸在含HBF₄的存在下反应,原位生成四配位的双(合)(羟基)苯基-λ³-烷复合物作为活性氧化剂。
  • Heterocyclic Bis-Cations as Starting Hits for Design of Inhibitors of the Bifunctional Enzyme Histidine-Containing Protein Kinase/Phosphatase from <i>Bacillus</i> <i>s</i><i>ubtilis</i>
    作者:Helena Ramström、Maryline Bourotte、Claude Philippe、Martine Schmitt、Jacques Haiech、Jean-Jacques Bourguignon
    DOI:10.1021/jm021043o
    日期:2004.4.1
    phosphorylation of HPr (histidine-containing protein) at Ser-46 by the ATP-dependent HPr kinase, which in Bacillus subtilis, Lactobacillus casei, and Staphylococcus xylosus also exhibits phosphatase activity and is thus a bifunctional enzyme (HPrK/P). Since deficiency of HPrK/P in S. xylosus, L. casei, and B. subtilis mutants leads to severe growth defects, inhibitors of the enzyme could form a new family of antibiotic
    在低鸟嘌呤和低胞嘧啶革兰氏阳性细菌中碳分解代谢物阻遏/激活的主要机制似乎涉及到ATP依赖性HPr激酶在Ser-46处HPr(含组酸的蛋白)的磷酸化,该酶在枯草芽孢杆菌中,干酪乳杆菌和木糖葡萄球菌也具有磷酸酶活性,因此是一种双功能酶(HPrK / P)。由于木糖链球菌,干酪乳杆菌和枯草芽孢杆菌突变体中HPrK / P的缺乏会导致严重的生长缺陷,因此该酶的抑制剂可能会形成一个新的抗生素药物家族。这项研究的目的是筛选一个内部化学文库,以鉴定作为枯草芽孢杆菌中HPrK / P抑制剂的命中物,并使用放射性体外测定法从命中优化中进一步提取结构特征的其他信息。对称的双阳离子化合物LPS 02-10-L-D09(2a)具有桥接两个2-氨基苯并咪唑部分的12个碳原子的烷基连接基,被确定为具有10 microM的EC(50)值的非ATP模拟化合物在以HPr为底物的激酶测定中 该物质还抑制了添加无机磷酸盐后触发的HPrK
  • AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
    申请人:Leadbetter Michael R.
    公开号:US20090149465A1
    公开(公告)日:2009-06-11
    The invention provides aminotetralin compounds of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , n, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    该发明提供了公式(I)的基四化合物:其中R1、R2、R3、R4、R5、R6、R7、n和m在规范中定义,或其药用可接受盐,这些化合物是μ阿片受体的拮抗剂。该发明还提供了包含这种化合物的药物组合物,使用这种化合物治疗与μ阿片受体活性相关的疾病的方法,以及用于制备这种化合物的过程和中间体。
  • Adamantyl-substituted polycyclic acetylene compounds and
    申请人:Centre International de Recherches Dermatologiques Galderma
    公开号:US05574036A1
    公开(公告)日:1996-11-12
    Novel pharmaceutically/cosmetically-active adamantyl-substituted polycyclic acetylene compounds have the structural formula (I): ##STR1## wherein Ar is a radical having one of the formulae (a)-(f): ##STR2## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular, bone and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.
    新型具有药用/化妆活性的脂环己基取代多环乙炔化合物具有结构式(I):其中Ar是具有式(a)-(f)之一的基团,对于治疗广泛的疾病状态是有用的,无论是人类还是兽医,例如皮肤病、风湿病、呼吸系统疾病、心血管疾病、骨骼疾病和眼科疾病,以及治疗哺乳动物的皮肤和毛发状况/疾病。
查看更多